Daniela M Zisterer
Overview
Explore the profile of Daniela M Zisterer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ana G, Malebari A, Noorani S, Fayne D, OBoyle N, Zisterer D, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
18(1).
PMID: 39861179
The synthesis of ()-1-(1,3-diphenylallyl)-1-1,2,4-triazoles and related compounds as anti-mitotic agents with activity in breast cancer was investigated. These compounds were designed as hybrids of the microtubule-targeting chalcones, indanones, and the...
2.
McKenna S, Florea B, Zisterer D, van Kasteren S, McGouran J
RSC Chem Biol
. 2024 Aug;
5(8):776-786.
PMID: 39092446
Affinity-based probes are valuable tools for detecting binding interactions between small molecules and proteins in complex biological environments. Metalloproteins are a class of therapeutically significant biomolecules which bind metal ions...
3.
Gao T, Magnano S, Rynne A, OKane L, Barroeta P, Zisterer D
Exp Cell Res
. 2024 Mar;
437(1):113995.
PMID: 38490621
Purpose: Oral Squamous Cell Carcinoma (OSCC) is the 6th most common cancer worldwide. It is generally aggressive and closely associated with chemoresistance and poor survival. There is accumulating evidence for...
4.
McLoughlin E, Twamley B, OBrien J, Barroeta P, Zisterer D, Meegan M, et al.
Bioorg Chem
. 2023 Oct;
141:106877.
PMID: 37804699
The synthesis and biochemical activity of a series of chiral trans 3-hydroxyl β-lactams targeting tubulin is described. Synthesis of the series of enantiopure β-lactams was achieved using chiral derivatising reagent...
5.
Wang S, Malebari A, Greene T, Kandwal S, Fayne D, Nathwani S, et al.
Pharmaceuticals (Basel)
. 2023 Jul;
16(7).
PMID: 37513912
A series of novel 3-(prop-1-en-2-yl)azetidin-2-one, 3-allylazetidin-2-one and 3-(buta-1,3-dien-1-yl)azetidin-2-one analogues of combretastatin A-4 (CA-4) were designed and synthesised as colchicine-binding site inhibitors (CBSI) in which the ethylene bridge of CA-4 was...
6.
Barroeta P, OSullivan M, Zisterer D
J Cancer Res Clin Oncol
. 2023 Apr;
149(11):8379-8391.
PMID: 37079050
Purpose: Malignant rhabdoid tumour (MRT) is a rare and aggressive childhood malignancy that occurs in the kidneys or central nervous system and is associated with very poor prognosis. Chemoresistance is...
7.
Malebari A, Duffy Morales G, Twamley B, Fayne D, Khan M, McLoughlin E, et al.
Pharmaceuticals (Basel)
. 2022 Sep;
15(9).
PMID: 36145265
The stilbene combretastatin A-4 (CA-4) is a potent microtubule-disrupting agent interacting at the colchicine-binding site of tubulin. In the present work, the synthesis, characterisation and mechanism of action of a...
8.
Barroeta P, Magnano S, OSullivan M, Zisterer D
Cancer Treat Res Commun
. 2022 Jun;
32:100584.
PMID: 35679755
Malignant rhabdoid tumour (MRT) is a rare and aggressive paediatric tumour that typically arises in the kidneys or central nervous system (CNS). The malignancy often affects patients under the age...
9.
Coyle R, OSullivan M, Zisterer D
Cancer Treat Res Commun
. 2022 May;
32:100579.
PMID: 35613525
Malignant rhabdoid tumour (MRT) is a rare, aggressive paediatric malignancy most commonly diagnosed in those below the age of three. MRTs can arise in soft tissue but are more often...
10.
Amet R, Previtali V, Mihigo H, Sheridan E, Brophy S, Hante N, et al.
Life Sci
. 2021 Dec;
290:120236.
PMID: 34953891
Aims: We have recently described a novel guanidinium-based compound, VP79s, which induces cytotoxicity in various cancer cell lines. Here, we aim to investigate the activity of VP79s and associated mechanisms...